Education
About Us
Working with TipRanks
Follow Us
Ascelia Pharma AB (SE:ACE)
:ACE
ACE Stock Chart & Stats
kr3.07
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.07
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr2.31 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
€390.59M
Enterprise Valuekr440.84M
Total Cash (Recent Filing)€72.28M
Total Debt (Recent Filing)€1.18M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Feb 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding126,815,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-2.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr2.31 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is €390.59M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Feb 05, 2026 which is in 54 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on Nov 05, 2025. The company reported -kr0.133 earnings per share for the quarter, missing the consensus estimate of -kr0.1 by -kr0.033.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 126,815,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.133 in its last earnings report, missing expectations of -kr0.1. Following the earnings report the stock price went down -1.948%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (ACE) is a Swedish specialty pharmaceutical company focused on the development of novel drugs that address unmet medical needs, primarily in the field of oncology. The company's lead product candidate, Orviglance (formerly known as Mangoral), is an oral imaging drug designed to enhance the visualization of liver metastases in patients with impaired kidney function undergoing MRI scans. Ascelia Pharma operates within the pharmaceutical sector, with a commitment to improving diagnostic procedures and treatment options for cancer patients.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―